ADAPTIVE BIOTECHNOLOGIES CORPORATION - COMMON STOC

Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

05 Aug 2025 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Second Quarter 2025 Financial Results on August 5, 2025

15 Jul 2025 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

01 Jul 2025 04:30:07 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

30 May 2025 04:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

28 May 2025 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

01 May 2025 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

10 Apr 2025 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

08 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

11 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

11 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

05 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

22 Jan 2025 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

14 Jan 2025 04:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

07 Jan 2025 04:30:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

02 Jan 2025 13:05:00 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

07 Dec 2024 15:30:22 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

03 Dec 2024 04:30:25 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

07 Nov 2024 13:05:01 By Nasdaq GlobeNewswire

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

07 Nov 2024 04:30:55 By Nasdaq GlobeNewswire

Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

09 Oct 2024 13:05:00 By Nasdaq GlobeNewswire